Damora Therapeutics, Inc. Common Stock (DMRA) Expected to Announce Quarterly Earnings on Friday

Key Points

• Q1 2026 earnings are expected Friday, April 24, with analysts projecting EPS of ($0.3004) and an earnings call scheduled for April 30 at 4:00 PM ET.
• The stock opened at $27.00 with a market cap of $1.63 billion and a 12‑month range of $2.36–$38.33; analysts give an average rating of “Moderate Buy” and an average price target of $44.25.
• Damora is a clinical‑stage biotech developing galectin‑3 and LOXL2 inhibitors, with lead programs GB0139 (inhaled for fibrosing lung disease) and GB1211 (oral for systemic fibrotic disorders).

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) is expected to be issuing its Q1 2026 resultson Friday, April 24th. Analysts expect the company to announce earnings of ($0.3004) per share for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 30, 2026 at 4:00 PM ET.

Damora Therapeutics, Inc. Common Stock Trading Up 1.5%

Shares of Damora Therapeutics, Inc. Common Stock stock opened at $27.00 on Friday. The business's 50 day simple moving average is $26.96 and its 200-day simple moving average is $21.83. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -2.23 and a beta of 1.59. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.36 and a twelve month high of $38.33.

Analyst Upgrades and Downgrades

Several analysts recently commented on DMRA shares. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a "hold" rating in a research report on Friday, January 9th. Weiss Ratings restated a "sell (e+)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, February 2nd. Guggenheim restated a "buy" rating and issued a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Finally, Leerink Partners started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, January 7th. They issued an "outperform" rating and a $46.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock presently has an average rating of "Moderate Buy" and an average price target of $44.25.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several large investors have recently added to or reduced their stakes in DMRA. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $40,000. Virtu Financial LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $49,000. Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $76,000. Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at $100,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $266,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.